TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Two products from the adipose-derived stem cell technology platform are currently in clinical development. - Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn’s disease patients. On July 4, 2016, we entered into a licensing agreement with Takeda, a large pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to commercialize Cx601 for complex perianal fistulas outside the United States. - Cx611 has completed a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis.  Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product, AlloCSC-01, is currently in a Phase II clinical trial in acute myocardial infarction (AMI). In addition, the second product candidate from the cardiac stem cell-based platform acquired from Coretherapix, AlloCSC-02, is being developed in a chronic indication. TiGenix is based in Leuven, Belgium, and has operations in Madrid, Spain.
Show more
TypeSubsidiary
Parent CompanyTakeda Pharmaceutical
HQLeuven, BE
Founded2000
Websitetigenix.com
Cybersecurity ratingAMore
TiGenix was founded in 2000 and is headquartered in Leuven, BE

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at TiGenix

Claudia DAugusta

Claudia DAugusta

Chief Financial Officer and General Manager
Wilfried Dalemans

Wilfried Dalemans

CTO
Marie Paule Richard

Marie Paule Richard

Chief Medical Officer
Maria Pascual

Maria Pascual

Vice President, Regulatory Affairs and Corporate Quality
Mary Carmen Diez

Mary Carmen Diez

Vice President, Medical Affairs and Commercialisation
Susana Rojo

Susana Rojo

Director of Human Resources
Show more

TiGenix Office Locations

TiGenix has an office in Leuven
Leuven, BE (HQ)
12 Romeinse straat
Show all (1)

TiGenix Financials and Metrics

Summary Metrics

Founding Date

2000

Total Funding

$37.5 m

Investors

TiGenix is a subsidiary of Takeda Pharmaceutical

TiGenix Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

TiGenix Online and Social Media Presence

Embed Graph

TiGenix News and Updates

Anal Fistula Treatment Market to Gain US$ 800 Mn in 2026, Says TMR

ALBANY, New York, June 19, 2018 /PRNewswire/ -- Transparency Market Research (TMR) has published a new report titled, "Anal Fistula Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018-2026". According to the report, the global anal fistula...

Takeda to add plant, 70 jobs in Ireland as it builds on deal for TiGenex

Takeda, which recently announced a $627 million deal to buy biotech TiGenix, is upping its bet on its stem cell therapy investment, with a new plant and 70 jobs at its manufacturing site in Ireland.

Bone Grafts And Substitutes Market Expand Their Businesses With New Investments by 2025

Bone grafts and substitutes (BGS) comprise the products that are used for the replacement of missing bones or to repair bone fractures. Posted via Industry Today. Follow us on Twitter @IndustryToday

TiGenix Blogs

Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period (EN – NL – FR – ES)

Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period (EN – NL – FR – ES)

Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid in respect of TiGenix and Commencement of Simplified Squeeze-out and Intention to Delist the ADSs from Nasdaq, Terminate the ADS Facility and Terminate TiGenix’s U.S. Reporting Obligations (EN – NL – FR – ES)

Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid in respect of TiGenix and Commencement of Simplified Squeeze-out and Intention to Delist the ADSs from Nasdaq, Terminate the ADS Facility and Terminate TiGenix’s U.S. Reporting Oblig…

Transparency Information ( EN – NL )

Transparency Information ( EN – NL )

Transparency notification pursuant to Article 14 of the Law of May 2, 2007

Transparency notification pursuant to Article 14 of the Law of May 2, 2007 (EN – NL)

Transparency notifications pursuant to Article 14 of the Law of May 2, 2007

Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 (EN – NL)

Transparency notification pursuant to Article 14 of the Law of May 2, 2007 ( EN – NL )

Transparency notification  pursuant to Article 14 of the Law of May 2, 2007 ( EN – NL )
Show more

TiGenix Frequently Asked Questions

  • When was TiGenix founded?

    TiGenix was founded in 2000.

  • Who are TiGenix key executives?

    TiGenix's key executives are Claudia DAugusta, Wilfried Dalemans and Marie Paule Richard.

  • How many employees does TiGenix have?

    TiGenix has 57 employees.

  • Who are TiGenix competitors?

    Competitors of TiGenix include Kither Biotech, CANbridge Life Sciences and Zytoprotec.

  • Where is TiGenix headquarters?

    TiGenix headquarters is located at 12 Romeinse straat, Leuven.

  • Where are TiGenix offices?

    TiGenix has an office in Leuven.

  • How many offices does TiGenix have?

    TiGenix has 1 office.